These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2476910)

  • 1. Intraventricular injections of galanin counteract development of head twitches induced by the 5-HT-2 agonist 1-(2,5-dimethoxyphenyl-4-bromo)-2-aminopropane.
    Ogren SO; Fuxe K
    Acta Physiol Scand; 1989 Jun; 136(2):297-8. PubMed ID: 2476910
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment.
    Leysen JE; Janssen PF; Niemegeers CJ
    Eur J Pharmacol; 1989 Apr; 163(1):145-9. PubMed ID: 2545460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
    Glennon RA; Young R; Benington F; Morin RD
    J Med Chem; 1982 Oct; 25(10):1163-8. PubMed ID: 7143352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congeners of DOM: effect of distribution of the evaluation of pharmacologic data.
    Barfknecht CF; Caputo JF; Tobin MB; Dyer DC; Standirdge RT; Howell HG; Goodwin WR; Partyka RA; Gylys JA; Cavanagh RL
    NIDA Res Monogr; 1978; (22):16-26. PubMed ID: 101880
    [No Abstract]   [Full Text] [Related]  

  • 5. Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
    Glennon RA; Bondarev ML; Khorana N; Young R; May JA; Hellberg MR; McLaughlin MA; Sharif NA
    J Med Chem; 2004 Nov; 47(24):6034-41. PubMed ID: 15537358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
    Nabeshima T; Yamaguchi K; Ishikawa K; Furukawa H; Kameyama T
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1139-46. PubMed ID: 2826756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraventricular injections of galanin reduces 5-HT metabolism in the ventral limbic cortex, the hippocampal formation and the fronto-parietal cortex of the male rat.
    Fuxe K; Ogren SO; Jansson A; Cintra A; Härfstrand A; Agnati LF
    Acta Physiol Scand; 1988 Aug; 133(4):579-81. PubMed ID: 2465672
    [No Abstract]   [Full Text] [Related]  

  • 9. DOM and related 2,5-dimethoxy-4-alkylphenylisopropylamines: behavioral and serotonin receptor properties.
    Glennon RA; Doot DL; Young R
    Pharmacol Biochem Behav; 1981 Mar; 14(3):287-92. PubMed ID: 7232455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
    Barker EL; Sanders-Bush E
    Mol Pharmacol; 1993 Oct; 44(4):725-30. PubMed ID: 8232222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic and dopaminergic involvement in the mechanism of action of R-(-)-2,5-dimethoxy-4-bromoamphetamine (DOB) in cats.
    Rusterholz DB; Spratt JL; Long JP; Kelly TF
    Life Sci; 1978 Oct; 23(14):1499-506. PubMed ID: 713706
    [No Abstract]   [Full Text] [Related]  

  • 13. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
    Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
    J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of para-methoxyamphetamine and 2,5-dimethoxyamphetamine on serotonergic mechanisms.
    Tseng LF
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Sep; 304(2):101-5. PubMed ID: 581302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat.
    Misane I; Johansson C; Ogren SO
    Br J Pharmacol; 1998 Oct; 125(3):499-509. PubMed ID: 9806333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice.
    Yamamoto T; Ueki S
    Eur J Pharmacol; 1975; 32(02):156-62. PubMed ID: 1149803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines.
    Morin RD; Benington F; Mitchell SR; Beaton JM; Bradley RJ; Smythies JR
    Experientia; 1975 Jan; 31(1):93-5. PubMed ID: 234850
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of rigid analogues to probe hallucinogen receptors.
    Nichols DE; Weintraub HJ; Pfister WR; Yim GK
    NIDA Res Monogr; 1978; (22):70-83. PubMed ID: 101889
    [No Abstract]   [Full Text] [Related]  

  • 19. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain.
    Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
    J Pharmacol Exp Ther; 1991 Feb; 256(2):787-94. PubMed ID: 1847212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of chirality on serotonin receptor affinity.
    Glennon RA
    Life Sci; 1979 Apr; 24(16):1487-92. PubMed ID: 470548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.